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Drug-eluting stents may aﬀect the normal healing process of the vessel wall and the remodeling process and may lead to late
stent malapposition (LSM). The known incidence of this phenomen originates from short-term angiographic follow-up studies.
We describe a case report of very late stent malapposition and marked positive vessel remodeling 3 years after sirolimus-eluting
coronary stent implantation. Angiography performed one year after stent implantation was normal. Thus, the abnormalities
developed sometime between years 1 and 3. The cause is unknown, but it is reasonable to suggest a local eﬀect of the
medication/polymer of the stent. LSM rate and aneurysmal formation is higher in DES than in BMS and may be associated
with increased risk for late stent thrombosis. Currently, the risk of very late stent thrombosis after DES implantation is of major
concern. As observed in this case report, LSM might occur and develop very late. This has signiﬁcant consequences especially to
the many asymptomatic patients with DES implanted many years ago and the recommendation of dual antiplatelet therapy. More
studies with late and very late follow up are needed to better deﬁne this ﬁnding, its mechanism, how to avoid it, and how to treat
it properly.
1.Introduction
Positive remodeling, regression of neointimal proliferation,
and late malapposition were described with brachytherapy
[1]. Major attention recently has been focused on late
complications after drug-eluting stents (DESs) implantation
[2–6]. DES may aﬀect the normal healing process of the
vessel wall and the remodeling process and may lead to late
stent malapposition (LSM) [7–9]. We describe a case report
of very late stent malapposition and marked positive vessel
remodeling 3 years after sirolimus-eluting coronary stent
(SES) implantation.
2.CaseReport
A-45year-old patient with history of hypercholesterolemia
and no diabetes mellitus was admitted to our hospital on
April 2005 for elective coronary angiography for typical
angina pectoriswithCanadianCardiovascularSociety(CCS)
score of 3. Three-vessel disease was diagnosed: 75% stenosis
ofthemid-leftanteriordescendingartery (LAD),75%steno-
sis of the mid-left circumﬂex artery (LtCx), and a chronic
total occlusion (CTO) of the mid right coronary artery
(RCA). Staging procedure was decided and a 3 × 18mm SES
was implanted to the mid-LtCx in the index procedure. A-
week later another 3 × 18mm SES was implanted to the mid
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stents (BMSs) were implanted in the mid-RCA (Motion
3 × 30mm and Clearﬂex 2.5 × 13mm). On April 2006,
a year later, the patient was readmitted for typical anginal
syndrome. Angiography revealed that both SESs in the LAD
and in the LtCx were patent. The SESs were patent with
very minimal angiographic positive remodeling around each
of the SES stents. There was focal in-stent restenosis in the
BMSintheRCA.Duetoconcernsabouttherapycompliance,
we decided to treat the patient with balloon dilatation only
without stent implantation.2 ISRN Cardiology
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Figure 1: Mid-LAD aneurysm.
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Figure 2: Mid-LtCx aneurysm.
In 2008,three yearsaftertheindex hospitalization,dueto
angina recurrence, the patient underwent another coronary
angiography. The RCA stents were patent. However, as com-
pared to the images obtained two years prior, a signiﬁcant
positive remodeling evolved and formed a large peristent
aneurysmal defect around both SES in the mid-LAD and
in the mid-LtCx (Figures 1 and 2). Intravascular ultrasound
(IVUS) to the LAD and the LtCx conﬁrmed the positive
remodeling and the presence of very LSM in both SESs
(Figures 3 and 4).
3.Discussion
We report a case report of very late LSM with SES. There
was deterioration in the angiographic appearance from
1 year to 3 years after stenting. Thus, the abnormalities
developed sometime between years 1 and 3. The cause is
unknown, but it is reasonable to suggest a local eﬀect of the
medication/polymer of the stent.
LSM rate and aneurysmal formation is higher in DES
than in BMS [3–5]. The mechanism of this phenomenon
remains unclear [2–9]. Several hypotheses have been sug-
gested; the ﬁrst is that the antiproliferative drug may exclude
theproliferationoftissueinthevoidinitiallypresentbetween
the struts and the vessel wall. Second, the drug may induce
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Figure 3: IVUS of LAD showing the stent struts and the “black
hole” which was formed (dashed orange lines).
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Figure 4: IVUS of LtCx showing the stent struts and the “black
hole” which was formed (yellow lines).
apoptosisornecrosis, creatinganew spacebetweenthevessel
wall and the struts initially well apposed. The third suggests
that the drug may prevent myoblasts proliferation in an
organized thrombus which will eventually dissolve creating
an empty space between the struts and the vessel wall.
Previous reports demonstrated aneurysmal formation at
the edges of the stent in intravascular brachytherapy [1], as
well as after BMS implantation. Serial IVUS analysis from
the SIRIUS trial found an 8.7% incidence of LSM after
SES implantation, with LSM being observed primarily in
the middle portion of the stent. The same location was
observed in the present case report. The diﬀerent locations
of aneurysmal formation indicate involvement of diﬀerent
biologic processes in the focal positive remodeling and
subsequent development of LSM in SES. LSM as in our
case may occur due to profound localized inhibition of
neointimal formation in disease-free segments of the vessel,
delaying early reparative events that usually enable the vessel
wall to incorporate a stent. Flow dynamics in these segments
may also favor positive remodeling of the artery at sites ofISRN Cardiology 3
delayed neointimal formation, resulting in late-acquired
aneurysmal formation.
Other hypothesis includes extensive acute vessel dam-
age during the initial procedure, hypersensitivity reactions,
infectious processes, and phenomena resembling extreme
cases of late-acquired malapposition [5–9]. The large numb
er of hypothesis suggests that we do not know the pathogen-
esis, and worse than that we do not know how to prevent or
treat this ﬁnding.
What is the prognosis of patients with this ﬁnding?
According to the RAVEL and SIRIUS study followup at
4y e a r s[ 4] in the SES population only, there was a non
statistically signiﬁcant diﬀerence in MACE between the
patients with or without LSM (11.1% versus 16.3%, P =
.48), and the authors concluded that LSM appears to be an
IVUS ﬁnding without signiﬁcant impact on the incidence
of major adverse cardiac events even during long-term
followup.
In contrast, Hassan et al. [5] in a recent meta-analysis
compared BMSto DESLSM ratesand long-term followup in
seventeen studies. The risk of LSM in patients with DES was
fourtimes higher compared with BMS(OR = 4.36,CI 95%
1.74–10.94).Theriskoflatestentthrombosisinpatientswith
LSM was higher compared with those without LSM (OR =
6.51, CI 95% 1.34–34.91). The authors concluded that LSM
is strongly increased after DES implantation compared with
BMS, and furthermore, LSM seems to be associated with late
and very late stent thrombosis.
Currently, the risk of very late stent thrombosis after
DES implantation is of major concern. It seems that patients
with LSM are at increased risk for this adverse eﬀect. As
observed in this case report, LSM might unfortunately occur
and develop very late. This has signiﬁcant consequences
especially to the many asymptomatic patients with DES
implanted in their coronaries several years ago. We do not
know whether such LSM develops late many years after
DES implantation. We should maybe consider a longer
dual antiplatelet therapy. More studies with late and very
late followup are needed to better deﬁne this ﬁnding, its
mechanism, how to avoid it and how to treat it, properly.
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